8-K
filed July 26, 2024, 7:59 PM ET
ticker HOOK
CIK 0001760542
leadership
confidence high
sentiment neutral
materiality 0.85
HOOKIPA Pharma appoints Dr. Malte Peters CEO and Terry Coelho CFO; launches strategic review for HB-200
HOOKIPA Pharma Inc.
- Dr. Malte Peters appointed CEO & President effective July 22, 2024; salary $630k, RSU award $700k.
- Terry Coelho appointed EVP & CFO effective July 22, 2024; salary $480k, signing bonus $240k, RSU $450k.
- Former CEO Jörn Aldag and CFO Reinhard Kandera separated July 22, resigned from board July 23.
- Sean Cassidy appointed independent director and Audit Committee chair effective July 22.
- Company launches strategic review to focus on HB-200 and create shareholder value; no impact on operations or trials.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Malte Peters was appointed as Chief Executive Officer and President at HOOKIPA Pharma Inc..
- Action
- appointed
- Role
- Chief Executive Officer and President
Exact text from the filing
the Company’s board of directors (the “Board”) appointed Malte Peters, M.D., as the Company’s Chief Executive Officer and President, effective July 22, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Reinhard Kandera departed as Chief Financial Officer at HOOKIPA Pharma Inc..
- Action
- separated
- Role
- Chief Financial Officer
Exact text from the filing
On July 22, 2024, Reinhard Kandera separated as the Chief Financial Officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Reinhard Kandera resigned as Director at HOOKIPA Pharma Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Mr. Kandera also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Financial Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Joern Aldag departed as Chief Executive Officer at HOOKIPA Pharma Inc..
- Action
- separated
- Role
- Chief Executive Officer
Exact text from the filing
On July 22, 2024, Joern Aldag separated as the Chief Executive Officer of HOOKIPA Pharma Inc. (the “Company”).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Joern Aldag resigned as Director at HOOKIPA Pharma Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Mr. Aldag also resigned from his position as a director of the Company on July 23, 2024 following his separation as Chief Executive Officer
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.